Base de dados : MEDLINE
Pesquisa : D27.505.696.875 [Categoria DeCS]
Referências encontradas : 464 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 47 ir para página                         

  1 / 464 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28441461
[Au] Autor:Gunnala V; Melnick A; Irani M; Reichman D; Schattman G; Davis O; Rosenwaks Z
[Ad] Endereço:The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York, United States of America.
[Ti] Título:Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles.
[So] Source:PLoS One;12(4):e0176019, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate pregnancy outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS) using a sliding scale hCG protocol to trigger oocyte maturity and establish a threshold level of serum b-hCG associated with optimal oocyte maturity. DESIGN: Retrospective cohort. SETTING: Academic medical center. PATIENTS: Fresh IVF cycles from 9/2004-12/2011. INTERVENTION: 10,427 fresh IVF-ICSI cycles met inclusion criteria. hCG was administered according to E2 level at trigger: 10,000IU vs. 5,000IU vs. 4,000IU vs. 3,300IU vs. dual trigger (2mg leuprolide acetate + 1,500IU hCG). Serum absorption of hCG was assessed according to dose and BMI. MAIN OUTCOME MEASURES: Oocyte maturity was analyzed according to post-trigger serum b-hCG. Fertilization, clinical pregnancy, live birth and OHSS rates were examined by hCG trigger dose. RESULTS: Post-trigger serum b-hCG 20-30, 30-40, and 40-50 mIU/mL was associated with reduced oocyte maturity as compared b-hCG >50 (67.8% vs. 71.4% vs. 73.3% vs. 78.9%, respectively, P<0.05). b-hCG 20-50 mIU/mL was associated with a 40.1% reduction in live birth (OR 0.59, 95% CI 0.41-0.87). No differences in IVF outcomes per retrieval were seen for varying doses of hCG or dual trigger when controlling for patient age. The incidence of moderate to severe OHSS was 0.13% (n = 14) and severe OHSS was 0.03% (n = 4) of cycles. CONCLUSIONS: Moderate stimulation with sliding scale hCG at trigger and fresh transfer is associated with low rates of OHSS and favorable pregnancy rates. Doses as low as 3,300IU alone or dual trigger with 1,500IU are sufficient to facilitate oocyte maturity.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/uso terapêutico
Síndrome de Hiperestimulação Ovariana/prevenção & controle
Indução da Ovulação/métodos
Substâncias para o Controle da Reprodução/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/administração & dosagem
Feminino
Fertilização In Vitro
Seres Humanos
Meia-Idade
Síndrome de Hiperestimulação Ovariana/epidemiologia
Indução da Ovulação/efeitos adversos
Gravidez
Resultado da Gravidez
Taxa de Gravidez
Substâncias para o Controle da Reprodução/administração & dosagem
Estudos Retrospectivos
Injeções de Esperma Intracitoplásmicas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Reproductive Control Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176019


  2 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28254221
[Au] Autor:Li Y; Luo K; Tang Y; Lin G; Lu G; Gong F
[Ad] Endereço:Reproductive & Genetic Hospital of Citic-Xiangya, Changsha, Hunan, China.
[Ti] Título:Progesterone/estradiol ratio <0.25 on the day of human chorionic gonadotropin administration is associated with adverse pregnancy outcomes in prolonged protocols for in vitro fertilization/intracytoplasmic sperm injection.
[So] Source:Taiwan J Obstet Gynecol;56(1):27-31, 2017 Feb.
[Is] ISSN:1875-6263
[Cp] País de publicação:China (Republic : 1949- )
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: It has been suggested that a progesterone/estradiol ratio (P/E2) ≥ 1.0 on the day of human chorionic gonadotropin (hCG) administration indicates premature luteinization and might be associated with an adverse pregnancy; however, a lower limit of this ratio has not been determined. We aimed to identify a lower limit of P/E2 that correlates significantly with an increase in adverse pregnancies in patients undergoing a prolonged in vitro fertilization/intracytoplasmic sperm injection therapy. MATERIALS AND METHODS: This retrospective analysis involved 7451 patients who received the first cycle of in vitro fertilization/intracytoplasmic sperm injection therapy treatment at the Reproductive and Genetic Hospital of Citic-Xiangya between January 2008 and April 2012. Patients were stratified into six groups according to their P/E2 on the day of hCG administration. Primary pregnancy outcomes, rates of implantation, clinical pregnancy, ongoing pregnancies, spontaneous abortions, and live births were recorded. The association between P/E2 on the day of hCG administration and primary pregnancy outcomes was assessed using logistic regression analysis. RESULTS: The rates of implantation (23.85-33.44%), clinical pregnancy (47.42-67.12%), ongoing pregnancy (40.83-61.48%), and live birth (34.40-57.65%) were significantly decreased in patients with a P/E2 < 0.25. These indicators were significantly associated with P/E2, but no significant correlation was observed between P/E2 and early spontaneous abortion rate. CONCLUSION: P/E2 < 0.25 on the day of hCG administration was associated with adverse pregnancy outcomes in extended treatments of gonadotropin-releasing hormone agonist IVF/ICSI.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/administração & dosagem
Estradiol/sangue
Fertilização In Vitro/métodos
Infertilidade Feminina/terapia
Receptores de Progesterona/sangue
Substâncias para o Controle da Reprodução/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/sangue
Transferência Embrionária
Feminino
Seres Humanos
Infertilidade Feminina/sangue
Reserva Ovariana
Indução da Ovulação/métodos
Gravidez
Resultado da Gravidez
Estudos Retrospectivos
Injeções de Esperma Intracitoplásmicas/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Receptors, Progesterone); 0 (Reproductive Control Agents); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE


  3 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28041830
[Au] Autor:Fox C; Azores-Gococo D; Swart L; Holoch K; Savaris RF; Likes CE; Miller PB; Forstein DA; Lessey BA
[Ad] Endereço:Department of Obstetrics and Gynecology, Greenville Hospital System, Greenville, SC 29605.
[Ti] Título:Luteal phase HCG support for unexplained recurrent pregnancy loss - a low hanging fruit?
[So] Source:Reprod Biomed Online;34(3):319-324, 2017 Mar.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Recurrent pregnancy loss (RPL) is defined by two or more failed pregnancies and accounts for only 1-5% of pregnancy failures. Treatment options for unexplained RPL (uRPL) are limited. Previous studies suggest a link between delayed implantation and pregnancy loss. Based on this, a timely signal for rescue of the corpus luteum (CL) using human chorionic gonadotrophin (HCG) could improve outcomes in women with uRPL. This retrospective cohort study included 98 subjects with uRPL: 45 underwent 135 monitored cycles without HCG support; and 53 underwent 142 cycles with a single mid-luteal HCG injection. Based on Log-rank Mantel-Cox survival curves, miscarriage rate and time to pregnancy decreased in the HCG group (P = 0.0005). Women receiving luteal HCG support had an increased chance of an ongoing pregnancy compared with those not receiving it (RR = 2.4; 95% CI 1.4-3.6; number need to treat (NNT) = 7; 95% CI 4-18). Subjects receiving HCG support had a significant absolute risk reduction (ARR) of miscarriage (P < 0.001; ARR = 11.5%; 95% CI 3.6-19.5; NNT = 9(5-27). These data suggest restoration of synchrony and CL support improves outcomes in women with RPL. Further randomized controlled trials of luteal-phase HCG in women with RPL appears warranted.
[Mh] Termos MeSH primário: Aborto Habitual/tratamento farmacológico
Gonadotropina Coriônica/uso terapêutico
Fase Luteal
Substâncias para o Controle da Reprodução/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Gravidez
Resultado da Gravidez
Estudos Retrospectivos
Tempo para Engravidar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Reproductive Control Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE


  4 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27888394
[Au] Autor:Sahoo JK; Das SK; Sethy K; Mishra SK; Swain RK; Mishra PC; Sahoo SP
[Ad] Endereço:Department of Animal Nutrition, C.V.Sc. & A.H., OUAT, Bhubaneswar, India. jatinsahoo43@gmail.com.
[Ti] Título:Comparative evaluation of hormonal protocol on the performance of crossbred cattle.
[So] Source:Trop Anim Health Prod;49(2):259-263, 2017 Feb.
[Is] ISSN:1573-7438
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A total of 60 animals (38 cows, 22 heifers) were selected and were divided into three groups of 20 animals each (containing both anoestrus and repeat breeder) in which treatment was performed for 60 days. Group I: control (farmer practice), T group: group I + hormone (double synch), and T group: group I + hormone (Estra double synch). The growth performances were measured in terms of body weight and average daily gain (ADG). Blood collection was done at the start and end of the experiment for assessment of blood biochemical, hematological, and reproductive status of the animals. Results revealed significant improvement in growth and reproductive performances in treatment group as compared to control group. Higher percentage of conception was achieved in group III (60%) followed by group II (55%). The least percentage was in group I (15%), i.e., in control group. So it was found that the effect of treating the reproductive-disordered animals with Estra double synch gave comparatively better result than double synch hormonal application.
[Mh] Termos MeSH primário: Busserrelina/farmacologia
Bovinos/fisiologia
Indústria de Laticínios/métodos
Dinoprosta/análogos & derivados
Estradiol/análogos & derivados
Sincronização do Estro/efeitos dos fármacos
Substâncias para o Controle da Reprodução/farmacologia
[Mh] Termos MeSH secundário: Animais
Bovinos/crescimento & desenvolvimento
Dinoprosta/farmacologia
Estradiol/farmacologia
Feminino
Índia
Inseminação Artificial/veterinária
Reprodução
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Reproductive Control Agents); 1S4CJB5ZGN (estradiol 3-benzoate); 4TI98Z838E (Estradiol); B7IN85G1HY (Dinoprost); CT6BBQ5A68 (dinoprost tromethamine); PXW8U3YXDV (Buserelin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161127
[St] Status:MEDLINE
[do] DOI:10.1007/s11250-016-1186-3


  5 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27808664
[Au] Autor:Falagario M; Trerotoli P; Chincoli A; Cobuzzi I; Vacca MP; Falagario D; Nardelli C; Depalo R
[Ad] Endereço:a Unit of Pathophysiology of Human Reproduction and Gametes Cryopreservation, Department of General Surgery , Gynecology, Obstetrics and Anesthesiology, University Hospital of Bari, Consorziale Policlinico , Bari , Italy , and.
[Ti] Título:Dynamics of the development of multiple follicles by early versus late hCG administration in ART program.
[So] Source:Gynecol Endocrinol;33(2):105-108, 2017 Feb.
[Is] ISSN:1473-0766
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate, in patients stimulated with recombinant FSH and GnRH antagonists, whether triggering the final maturation of oocytes affects IVF outcomes. STUDY DESIGN: Five hundred and six IVF procedures were divided into three groups according to the timing of hCG administration: when at least 2 follicles reached the diameter of 17 mm, at least 2 follicles reached 18 mm and at least 2 follicles reached 20 mm. The main outcome was the number of mature oocyte that was the dependent variable of a multivariate model whose independents were, age, AFC, hCG timing, E2 levels at hCG day, number of follicles in different categories of dimension. Secondary endpoints were to compare fertilization, implantation and pregnancy rates in a multilevel multivariate model whose covariates were age, BMI, AFC, embryo quality and cause of infertility. RESULTS: Timing did not result a statistically significant factor influencing the number of oocytes collected, which was influenced by age, AFC, number of follicles between 12.1 and 15.9 mm and E2 levels. Implantation rate and pregnancy rate appear to be affected only by embryo quality. CONCLUSION: The number of oocytes collected and the probability of pregnancy are not associated with the time of hCG administration.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/farmacologia
Fertilização In Vitro/métodos
Oócitos/fisiologia
Avaliação de Resultados (Cuidados de Saúde)
Substâncias para o Controle da Reprodução/farmacologia
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/administração & dosagem
Feminino
Seres Humanos
Gravidez
Taxa de Gravidez
Substâncias para o Controle da Reprodução/administração & dosagem
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Reproductive Control Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161104
[St] Status:MEDLINE
[do] DOI:10.1080/09513590.2016.1239252


  6 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27642094
[Au] Autor:S V; C J; K C S; Jose S; Jose B; Philip R; I S BS
[Ad] Endereço:National Centre for Aquatic Animal Health, Cochin University of Science and Technology, Cochin 682 016, India.
[Ti] Título:Regulating gonad inhibition and vitellogenin/vitellin induction in Penaeus monodon using mature GIH fusion protein and polyclonal antisera.
[So] Source:Comp Biochem Physiol A Mol Integr Physiol;203:167-178, 2017 Jan.
[Is] ISSN:1531-4332
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Gonad inhibiting hormone (GIH), type II class of the CHH family neuropeptides, is released by the neurohaemal XO-SG complex of the eyestalk. The inhibitory function of GIH has a pivotal role in gonad development and reproduction. In this study, we report the expression and production of a thioredoxin-fused mature GIH protein (mf-PmGIH) of Penaeus monodon in a bacterial system and its use as antigen to raise polyclonal antiserum (anti-mf-PmGIH). The mature GIH gene of 237bp that codes for 79 amino acids, was cloned into the Escherichia coli thioredoxin gene fusion expression system. The expression vector construct (mf-PmGIH+pEt32a+) upon induction produced 32.16kDa mature GIH fusion protein (mf-PmGIH)·The purified fusion protein was used as exogenous GIH and as antigen to raise polyclonal antisera. The fusion protein when injected into juvenile shrimp significantly reduced vitellogenin/vitellin levels by 31.55% within 72h in comparison to the controls showing the gonad inhibiting property. Vitellogenin/vitellin levels were significantly induced by 74.10% within 6h when polyclonal antiserum (anti-mf-PmGIH - 1:500) was injected in P. monodon. Anti-mf-PmGIH immunolocalized GIH producing neurosecretory cells in the eyestalk of P. monodon. The present manuscript reports an innovative means of gonad inhibition and vitellogenin/vitellin induction with thioredoxin fused GIH and antisera developed.
[Mh] Termos MeSH primário: Proteínas de Artrópodes/farmacologia
Proteínas de Transporte/farmacologia
Desenho de Drogas
Hormônios de Invertebrado/farmacologia
Modelos Moleculares
Penaeidae/efeitos dos fármacos
Substâncias para o Controle da Reprodução/farmacologia
Vitelogênese/efeitos dos fármacos
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Anticorpos Neutralizantes/farmacologia
Aquicultura
Proteínas de Artrópodes/química
Proteínas de Artrópodes/genética
Proteínas de Artrópodes/metabolismo
Bioensaio
Proteínas de Transporte/química
Proteínas de Transporte/genética
Proteínas de Transporte/metabolismo
Sequência Conservada
Proteínas de Escherichia coli/química
Proteínas de Escherichia coli/genética
Proteínas de Escherichia coli/metabolismo
Proteínas de Escherichia coli/farmacologia
Olho
Feminino
Hormônios de Invertebrado/química
Hormônios de Invertebrado/genética
Hormônios de Invertebrado/metabolismo
Sistemas Neurossecretores/citologia
Sistemas Neurossecretores/efeitos dos fármacos
Sistemas Neurossecretores/fisiologia
Penaeidae/citologia
Penaeidae/fisiologia
Conformação Proteica
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes de Fusão/metabolismo
Proteínas Recombinantes de Fusão/farmacologia
Substâncias para o Controle da Reprodução/antagonistas & inibidores
Substâncias para o Controle da Reprodução/química
Substâncias para o Controle da Reprodução/metabolismo
Alinhamento de Sequência
Homologia Estrutural de Proteína
Tiorredoxinas/química
Tiorredoxinas/genética
Tiorredoxinas/metabolismo
Tiorredoxinas/farmacologia
Vitelinas/antagonistas & inibidores
Vitelinas/genética
Vitelinas/metabolismo
Vitelogeninas/antagonistas & inibidores
Vitelogeninas/genética
Vitelogeninas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Arthropod Proteins); 0 (Carrier Proteins); 0 (Escherichia coli Proteins); 0 (Invertebrate Hormones); 0 (Recombinant Fusion Proteins); 0 (Reproductive Control Agents); 0 (Vitellins); 0 (Vitellogenins); 138360-48-2 (vitellogenesis inhibiting hormone); 52500-60-4 (Thioredoxins)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161107
[St] Status:MEDLINE


  7 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27555316
[Au] Autor:Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
[Ad] Endereço:Center for Reproductive Medicine and Department of Gynecology and Obstetrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
[Ti] Título:Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
[So] Source:Am J Obstet Gynecol;216(1):42.e1-42.e10, 2017 Jan.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ovarian hyperstimulation syndrome is an iatrogenic complication of controlled ovarian stimulation. Early ovarian hyperstimulation syndrome occurs during luteal phase of controlled ovarian stimulation within 9 days after human chorionic gonadotropin trigger and reflects an acute consequence of this hormone on the ovaries. Late ovarian hyperstimulation syndrome occurs 10 or more days after human chorionic gonadotropin trigger and reflects increased endogenous human chorionic gonadotropin levels following pregnancy. Human chorionic gonadotropin stimulates granulosa-lutein cells to produce vascular endothelial growth factor messenger RNAs, which in turn raises serum vascular endothelial growth factor concentration and increases vascular permeability in women with ovarian hyperstimulation syndrome. Efforts to reduce the incidence and severity of ovarian hyperstimulation syndrome after oocyte retrieval, and in particular primary prevention efforts, are vital to prevent thrombogenesis and other serious complications. OBJECTIVE: The objective of the study was to compare the efficacy of letrozole, an aromatase inhibitor, with aspirin in primary prevention of early ovarian hyperstimulation syndrome and to compare vascular endothelial growth factor levels between groups. STUDY DESIGN: Participants in this prospective randomized trial included 238 participants undergoing cryopreservation of the whole embryos after oocyte retrieval with at least 1 of the following high-risk factors for ovarian hyperstimulation syndrome: oocyte retrieval ≥25; estradiol level ≥5000 pg/mL on the day of human chorionic gonadotropin administration; and clinical or ultrasonographic evidence of ovarian hyperstimulation syndrome on the day of oocyte retrieval, such as ultrasonographic evidence of ascites. After human chorionic gonadotropin triggering, experimental (119 cases) and control (119 cases) groups received letrozole and aspirin, respectively, for 5 days. The 5 categories of ovarian hyperstimulation syndrome include no, yes-mild, yes-moderate, yes-severe, and yes-critical. The primary outcome was the incidence and severity of early ovarian hyperstimulation syndrome. The secondary outcome included vascular endothelial growth factor level both on the second and seventh day after the human chorionic gonadotropin trigger, and clinical and laboratory features of ovarian hyperstimulation syndrome symptoms. RESULTS: The incidence of ovarian hyperstimulation syndrome was significantly higher in women receiving aspirin, compared with letrozole (90.2% vs 80.4%, P = .044). Moderate and severe ovarian hyperstimulation syndrome was also higher in the aspirin group, 45.1%, compared with the letrozole group, 25.0% (P = .002). Moreover, the duration of luteal phase was shortened in letrozole group compared with aspirin group (8.1 ± 1.1 days vs 10.5 ± 1.9 days, P < .001). The vascular endothelial growth factor level was significantly higher in the letrozole-treated group than aspirin-treated group (0.49 ± 0.26 vs 0.42 ± 0.22, P = .029). CONCLUSION: Letrozole was more effective than aspirin in decreasing the incidence of moderate and severe early-onset ovarian hyperstimulation syndrome. Our results indicate that ovarian hyperstimulation syndrome might be caused through a luteolytic effect rather than through modulation of vascular endothelial growth factor, racing by a decline in estradiol and termination of early-onset ovarian hyperstimulation syndrome in advance in high-risk women with cryopreservation of the whole embryos.
[Mh] Termos MeSH primário: Inibidores da Aromatase/uso terapêutico
Nitrilos/uso terapêutico
Síndrome de Hiperestimulação Ovariana/prevenção & controle
Triazóis/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios não Esteroides/uso terapêutico
Ascite/diagnóstico por imagem
Ascite/etiologia
Aspirina/uso terapêutico
Gonadotropina Coriônica/uso terapêutico
Estradiol/metabolismo
Feminino
Seres Humanos
Fase Luteal
Recuperação de Oócitos/métodos
Síndrome de Hiperestimulação Ovariana/complicações
Síndrome de Hiperestimulação Ovariana/diagnóstico por imagem
Síndrome de Hiperestimulação Ovariana/metabolismo
Indução da Ovulação/métodos
Prevenção Primária
Substâncias para o Controle da Reprodução/uso terapêutico
Medição de Risco
Índice de Gravidade de Doença
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Aromatase Inhibitors); 0 (Chorionic Gonadotropin); 0 (Nitriles); 0 (Reproductive Control Agents); 0 (Triazoles); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 4TI98Z838E (Estradiol); 7LKK855W8I (letrozole); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160825
[St] Status:MEDLINE


  8 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27449969
[Au] Autor:Huang P; Wei L; Li X
[Ad] Endereço:a Department of Reproductive Medicine , Liuzhou Maternity and Child Healthcare Hospital , Guangxi , China.
[Ti] Título:A study of intrauterine infusion of human chorionic gonadotropin (hCG) before frozen-thawed embryo transfer after two or more implantation failures.
[So] Source:Gynecol Endocrinol;33(1):67-69, 2017 Jan.
[Is] ISSN:1473-0766
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the effect of intrauterine infusion of human chorionic gonadotropin (hCG) before frozen-thawed embryo transfer (FET) after two or more implantation failures (TIFs). METHODS: The study was a prospective randomized single-blind study of 161 cycles in patients undergoing FET who had TIFs. The intervention group received an intrauterine injection of 1000 IU of hCG before embryo transfer (ET) (n = 62). A placebo group (n = 49) received an intrauterine injection of physiological saline before ET. A control group (n = 50) did not receive an intrauterine injection. Clinical pregnancy rates, abortion rates, and ongoing pregnancy rates were compared between the three groups. RESULTS: The clinical pregnancy rates were 59.68%, 53.06%, and 32.00% in the hCG group, placebo group, and control group, respectively. The clinical pregnancy rates were significantly higher in the hCG and placebo groups than in the control group. There were no significant differences in the abortion rates among the three groups. CONCLUSION: An intrauterine administration of hCG before FET significantly improved the pregnancy rates after TIFs. But local injury caused by the operation of intrauterine perfusion may play an important role in improving clinical pregnancy rates.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/farmacologia
Implantação do Embrião
Transferência Embrionária/métodos
Fertilização In Vitro/métodos
Avaliação de Resultados (Cuidados de Saúde)
Substâncias para o Controle da Reprodução/farmacologia
[Mh] Termos MeSH secundário: Adulto
Gonadotropina Coriônica/administração & dosagem
Criopreservação
Feminino
Seres Humanos
Infusões Parenterais
Gravidez
Taxa de Gravidez
Substâncias para o Controle da Reprodução/administração & dosagem
Método Simples-Cego
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Reproductive Control Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160725
[St] Status:MEDLINE
[do] DOI:10.1080/09513590.2016.1207164


  9 / 464 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27852101
[Au] Autor:Reavey J; Vincent K; Child T; Granne IE
[Ad] Endereço:Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headley Way, Oxford, UK, OX3 9DU.
[Ti] Título:Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation.
[So] Source:Cochrane Database Syst Rev;11:CD008720, 2016 11 16.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In vitro maturation (IVM) is a fertility treatment that involves the transvaginal retrieval of immature oocytes, and their subsequent maturation and fertilisation. Although the live birth rate is lower than conventional in vitro fertilisation (IVF) with ovarian stimulation, it is a useful treatment, as it avoids the risk of ovarian hyperstimulation syndrome (OHSS). Women with polycystic ovaries (PCO) or polycystic ovarian syndrome (PCOS) are at an increased risk of OHSS. Thus, IVM may be a more useful treatment in this patient group.Strategies to maximise the maturation rates of the immature oocytes are important. This review focuses on the administration of human chorionic gonadotrophin (hCG) prior to immature oocyte retrieval. OBJECTIVES: To determine the effectiveness and safety of hCG priming in subfertile women who are undergoing IVM treatment in the context of assisted reproduction. SEARCH METHODS: We searched the following electronic databases up to 29 August 2016: Cochrane Gynaecology and Fertility Group Specialised Register of controlled trials, CENTRAL, MEDLINE, Embase, PsycINFO, and CINAHL. We also searched the trial registries ClinicalTrials.gov and WHO ICTPR to identify ongoing and registered trials. We sought recently published papers not yet indexed in the major databases, and reviewed the reference lists of reviews and retrieved studies as sources of potentially relevant studies. There were no language restrictions. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared hCG priming with placebo or no priming in women undergoing IVM. We also included RCTs that compared different doses of hCG, or the timing of oocyte retrieval. The primary outcomes were live birth rate and miscarriage rate per woman randomised. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, and with a third author, assessed risk of bias and extracted data. We contacted the original authors where data were missing. For dichotomous outcomes, we used the Mantel-Haenszel method to calculate odds ratios (OR). For continuous outcomes, we calculated the mean differences (MD) between treatment groups. We assessed statistical heterogeneity using the I² statistic. We assessed the overall quality of the evidence using GRADE methods. MAIN RESULTS: We included four studies, with a total of 522 women, in the review. One of these studies did not report outcomes per woman randomised, and so was not included in formal analysis. Three studies investigated 10,000 units hCG priming compared to no priming. One study investigated 20,000 units hCG compared to 10,000 units hCG priming. Three studies only included women with PCOS (N = 122), while this was an exclusion criteria in the fourth study (N = 400).We rated all four studies as having an unclear risk of bias in more than one of the seven domains assessed. The quality of the evidence was low, the main limitations being lack of blinding and imprecision.When 10,000 units hCG priming was compared to no priming, we found no evidence of a difference in the live birth rates per woman randomised (OR 0.65, 95% confidence intervals (CI) 0.24 to 1.74; one RCT; N = 82; low quality evidence); miscarriage rate (OR 0.60, 95% CI 0.21 to 1.72; two RCTs; N = 282; I² statistic = 21%; low quality evidence), or clinical pregnancy rate (OR 0.52, 95% CI 0.26 to 1.03; two RCTs, N = 282, I² statistic = 0%, low quality evidence). Though inconclusive, our findings suggested that hCG may be associated with a reduction in clinical pregnancy rates; 22% of women who received no priming achieved pregnancy, while between 7% and 23% of women who received hCG priming did so.The study comparing 20,000 units hCG with 10,000 units hCG did not report sufficient data to enable us to calculate odds ratios.No studies reported on adverse events (other than miscarriage) or drug reactions. AUTHORS' CONCLUSIONS: This review found no conclusive evidence that hCG priming had an effect on live birth, pregnancy, or miscarriage rates in IVM. There was low quality evidence that suggested that hCG priming may reduce clinical pregnancy rates, however, these findings were limited by the small number of data included. As no data were available on adverse events (other than miscarriage) or on drug reactions, we could not adequately assess the safety of hCG priming. We need further evidence from well-designed RCTs before we can come to definitive conclusions about the role of hCG priming, and the optimal dose and timing.
[Mh] Termos MeSH primário: Gonadotropina Coriônica/administração & dosagem
Técnicas de Maturação in Vitro de Oócitos
Infertilidade Feminina
Taxa de Gravidez
Substâncias para o Controle da Reprodução/administração & dosagem
[Mh] Termos MeSH secundário: Aborto Espontâneo/epidemiologia
Adulto
Gonadotropina Coriônica/efeitos adversos
Feminino
Seres Humanos
Nascimento Vivo/epidemiologia
Recuperação de Oócitos
Gravidez
Ensaios Clínicos Controlados Aleatórios como Assunto
Substâncias para o Controle da Reprodução/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Reproductive Control Agents)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE


  10 / 464 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27740929
[Au] Autor:Lee PA; Luce M; Bacher P
[Ti] Título:Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
[So] Source:J Pediatr Endocrinol Metab;29(11):1249-1257, 2016 Nov 01.
[Is] ISSN:2191-0251
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Peak gonadotropin-releasing hormone or agonist (GnRHa) stimulated luteinizing hormone (LH) testing with leuprolide acetate (LA) is commonly used to document suppression during therapy for central precocious puberty (CPP). The objective of the study was to investigate suitability of using basal LH levels to monitor GnRHa treatment and to determine optimal transition from 1-month to 3-month LA formulations via a post hoc analysis of a randomized, open-label, 6-month study. METHODS: A total of 42 children with CPP, pretreated with 7.5-, 11.25-, or 15-mg 1-month LA formulations were randomized to 11.25- or 30-mg 3-month LA. Basal LH/peak-stimulated LH levels were measured at weeks 0, 4, 8 and 12. Positive/negative predictive values and sensitivities/specificities were determined for basal LH vs. LH-stimulation results. RESULTS: Pretreatment with any 1-month formulation for the most part did not affect continuation of suppression after transitioning to 3-month formulation (mean peak-stimulated LH levels remained < 4 IU/L). Basal LH predicted suppression escape (basal LH-level cutoff ≥ 0.6 IU/L predicted 70% of those failing suppression). Tolerability was similar, regardless of dose. CONCLUSIONS: Our data indicate that a basal level of <0.60 IU/L is adequate for monitoring suppression approximately two-thirds of the time. Furthermore, the effectiveness and safety of 3-month LA treatments are not influenced by previous CPP therapies.
[Mh] Termos MeSH primário: Monitoramento de Medicamentos
Hormônio Liberador de Gonadotropina/agonistas
Leuprolida/administração & dosagem
Hormônio Luteinizante/sangue
Puberdade Precoce/tratamento farmacológico
Substâncias para o Controle da Reprodução/administração & dosagem
[Mh] Termos MeSH secundário: Criança
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/efeitos adversos
Preparações de Ação Retardada/uso terapêutico
Relação Dose-Resposta a Droga
Esquema de Medicação
Feminino
Hormônio Foliculoestimulante Humano/antagonistas & inibidores
Hormônio Foliculoestimulante Humano/sangue
Hormônio Foliculoestimulante Humano/secreção
Seres Humanos
Sistema Hipotálamo-Hipofisário/efeitos dos fármacos
Sistema Hipotálamo-Hipofisário/secreção
Leuprolida/efeitos adversos
Leuprolida/uso terapêutico
Hormônio Luteinizante/antagonistas & inibidores
Hormônio Luteinizante/secreção
Masculino
Microesferas
Ovário/efeitos dos fármacos
Ovário/secreção
Puberdade Precoce/sangue
Substâncias para o Controle da Reprodução/efeitos adversos
Substâncias para o Controle da Reprodução/uso terapêutico
Estudos Retrospectivos
Testículo/efeitos dos fármacos
Testículo/secreção
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Follicle Stimulating Hormone, Human); 0 (Reproductive Control Agents); 33515-09-2 (Gonadotropin-Releasing Hormone); 9002-67-9 (Luteinizing Hormone); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161015
[St] Status:MEDLINE



página 1 de 47 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde